$15.06
0.74% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$15.06
-0.92 5.76% 1M
-5.53 26.86% 6M
+0.64 4.44% YTD
+0.70 4.87% 1Y
-15.03 49.95% 3Y
-18.19 54.71% 5Y
-18.19 54.71% 10Y
NYSE, Closing price Fri, Dec 27 2024
+0.11 0.74%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $3.88b
Enterprise Value $11.86b
P/E (TTM) P/E ratio 2.99
EV/FCF (TTM) EV/FCF 15.88
EV/Sales (TTM) EV/Sales 1.85
P/S ratio (TTM) P/S ratio 0.61
P/B ratio (TTM) P/B ratio 7.87
Dividend yield 7.44%
Last dividend (FY24) $1.12
Revenue growth (TTM) Revenue growth 4.21%
Revenue (TTM) Revenue $6.41b
EBIT (operating result TTM) EBIT $1.50b
Free Cash Flow (TTM) Free Cash Flow $747.00m
Cash position $763.00m
EPS (TTM) EPS $5.04
P/E forward 3.91
P/S forward 0.61
EV/Sales forward 1.85
Short interest 7.09%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Organon & Co. forecast:

3x Buy
33%
4x Hold
44%
2x Sell
22%

Analyst Opinions

9 Analysts have issued a Organon & Co. forecast:

Buy
33%
Hold
44%
Sell
22%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6,409 6,409
4% 4%
100%
- Direct Costs 2,675 2,675
11% 11%
42%
3,734 3,734
0% 0%
58%
- Selling and Administrative Expenses 1,499 1,499
8% 8%
23%
- Research and Development Expense 473 473
11% 11%
7%
1,762 1,762
12% 12%
27%
- Depreciation and Amortization 260 260
14% 14%
4%
EBIT (Operating Income) EBIT 1,502 1,502
11% 11%
23%
Net Profit 1,301 1,301
122% 122%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Neutral
Business Wire
10 days ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th.
Positive
Seeking Alpha
about one month ago
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, e...
Neutral
Seeking Alpha
about 2 months ago
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant r...
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today